Tag: altimmune

March 19, 2019

Altimmune Announces Positive Results from NasoVAX Extension Study

Altimmune (NASDAQ:ALT) has announced positive data from its Phase 2 extension study of NasoVAX intranasal influenza vaccine candidate. As quoted...
January 29, 2019

Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress

Altimmune (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced results of its recently completed HepTcell Phase 1 clinical trial will be...
September 4, 2018

Altimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine

Altimmune (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced additional positive data from a Phase 2a study of its NasoVAX intranasal...